| John Schouten, PT, DPT | |
|
525 S Chandler Village Dr, Chandler, AZ 85226-5069 | |
| (602) 648-5444 | |
| (602) 772-3801 |
| Full Name | John Schouten |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 4 Years |
| Location | 525 S Chandler Village Dr, Chandler, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205400801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 12177812-2401 (Utah) | Secondary |
| 225100000X | Physical Therapist | LPT-32004 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dht Hand Therapy Limited Partnership | 0547362691 | 28 |
| Orthopedic Specialists Of North America Pllc | 7719014505 | 270 |
News Archive
The physical forces that guide how cells migrate-how they manage to get from place to place in a coordinated fashion inside the living body- are poorly understood. Scientists at the Harvard School of Public Health and the Institute for Bioengineering of Catalonia have, for the first time, devised a way to measure these forces during collective cellular migration.
LivaNova PLC, a market-leading medical technology company, today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve Stimulation Therapy® as Adjunctive Therapy in Real-world Patients with Difficult to Treat Depression.
Cardiac research in Sheffield has received a major boost from the British Heart Foundation in the form of an £800,000 award to develop a new gene therapy to treat cardiovascular disease (CVD).
BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.
› Verified 3 days ago
| Entity Name | Dht Hand Therapy Limited Partnership |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629137997 PECOS PAC ID: 0547362691 Enrollment ID: O20070221000195 |
News Archive
The physical forces that guide how cells migrate-how they manage to get from place to place in a coordinated fashion inside the living body- are poorly understood. Scientists at the Harvard School of Public Health and the Institute for Bioengineering of Catalonia have, for the first time, devised a way to measure these forces during collective cellular migration.
LivaNova PLC, a market-leading medical technology company, today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve Stimulation Therapy® as Adjunctive Therapy in Real-world Patients with Difficult to Treat Depression.
Cardiac research in Sheffield has received a major boost from the British Heart Foundation in the form of an £800,000 award to develop a new gene therapy to treat cardiovascular disease (CVD).
BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.
› Verified 3 days ago
| Entity Name | Orthopedic Specialists Of North America Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770812828 PECOS PAC ID: 7719014505 Enrollment ID: O20100428000061 |
News Archive
The physical forces that guide how cells migrate-how they manage to get from place to place in a coordinated fashion inside the living body- are poorly understood. Scientists at the Harvard School of Public Health and the Institute for Bioengineering of Catalonia have, for the first time, devised a way to measure these forces during collective cellular migration.
LivaNova PLC, a market-leading medical technology company, today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve Stimulation Therapy® as Adjunctive Therapy in Real-world Patients with Difficult to Treat Depression.
Cardiac research in Sheffield has received a major boost from the British Heart Foundation in the form of an £800,000 award to develop a new gene therapy to treat cardiovascular disease (CVD).
BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Schouten, PT, DPT Po Box 80217, Phoenix, AZ 85060-0217 Ph: (602) 385-2115 | John Schouten, PT, DPT 525 S Chandler Village Dr, Chandler, AZ 85226-5069 Ph: (602) 648-5444 |
News Archive
The physical forces that guide how cells migrate-how they manage to get from place to place in a coordinated fashion inside the living body- are poorly understood. Scientists at the Harvard School of Public Health and the Institute for Bioengineering of Catalonia have, for the first time, devised a way to measure these forces during collective cellular migration.
LivaNova PLC, a market-leading medical technology company, today announced the launch and enrollment of the first patient in the Global Prospective, Multi-center, Observational Post-market Study to Assess Short-, Mid- and Long-term Effectiveness and Efficiency of Vagus Nerve Stimulation Therapy® as Adjunctive Therapy in Real-world Patients with Difficult to Treat Depression.
Cardiac research in Sheffield has received a major boost from the British Heart Foundation in the form of an £800,000 award to develop a new gene therapy to treat cardiovascular disease (CVD).
BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial.
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.
› Verified 3 days ago